The Latest Breaking News on Pharma

Fainting and fatigue may signal onset of variant, experts say

Estee Lauder Cos Inc cut its full-year sales and profit forecasts on Wednesday, signaling a hit to sales from persistent COVID-19-related lockdowns and store closures in major market China. The New York-based company's shares were down about 5% in premarket trade. Sales growth of many US companies like Estee has…

If even Unilever, of all companies, is allowing its staff a 4 day work week then we know that shit works.

CSL Seqirus is paying $A312 million up-front to license next-generation mRNA technology from a small US company, Arcturus Therapeutics.

Gb Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation.

Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU)

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application. 

Timber Pharmaceuticals (TMBR) recently received an NYSE warning for not meeting the minimum trading price requirement for quite some time. The stock has lost 84% year-to-date. Given the company’s weak fundamentals, the stock could be a poor choice for investors enticed by its negligible price. Let’s discuss….

Consumer goods giant Unilever is expanding its four-day work week trial to Australia after impressive results in New Zealand.